key: cord-0814360-84wuoehq authors: Criscuolo, Elena; Diotti, Roberta A.; Strollo, Marta; Rolla, Serena; Ambrosi, Alessandro; Locatelli, Massimo; Burioni, Roberto; Mancini, Nicasio; Clementi, Massimo; Clementi, Nicola title: Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects date: 2020-11-01 journal: J Med Virol DOI: 10.1002/jmv.26605 sha: 9d5184081425b1b268ac2db69940dba0878cc718 doc_id: 814360 cord_uid: 84wuoehq Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Tracking the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive subjects certainly represents an urgent epidemiological need for facing coronavirus disease-2019 (COVID-19) pandemic waves worldwide. Additionally, commercially available serological assays are of pivotal importance from a diagnostic point of view, especially in those subjects with a clinical picture suggestive for COVID-19 but lacking a molecular-based confirmation of SARS-CoV-2 infection. 1 To date, several studies have characterized the kinetics of SARS-CoV-2-elicited antibodies evidencing immunoglobulin M (IgM) within 5 days from symptoms onset for and IgG within approximatively 7 days, 2-5 but the persistence of the humoral immunity towards SARS-CoV-2 seems to be poor. 6, 7 A plethora of serologic tests are invading the market, and some of them have been evaluated. 8 However, other assays deserve further analyses as there is no consensus so far on antigens used for the antibody testing nor for the antibody isotype to be detected. These last aspects can be of pivotal importance for evaluating antibody response to candidate vaccines, for selecting plasmas for clinical trials, and for dissecting unknown immunological aspects related to seroconversion. Indeed, according to WHO, as of 24th September 2020, no correlations between seroconversion, neutralizing activity, and immunity have been made. 9 In the present study, we evaluated the performances of two commercial serology tests, the LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche, on 46 COVID-19 patients and 85 sera collected before the current pandemic. Data obtained from both commercial assays were then compared to the neutralizing activity of each serum against a clinical isolate of SARS-CoV-2, a clinical isolate from a patient admitted to San Raffaele Hospital, Milan (Italy) during the early COVID-19 pandemic in Lombardy. The study was reviewed and approved by San Raffaele Hospital IRB in the COVID-19 Biobanking project "COVID-BioB" N°CE: 34/int/ 2020 19/March/2020 ClinicalTrials.gov Identifier: NCT04318366. Forty-six serum samples were randomly collected from laboratoryconfirmed symptomatic COVID-19 patients on their admission to the hospital (T0) and 15 days later (T15). Eighty-five "pre-pandemic" serum samples, spanning from 2012 to 2018, were also tested for the presence of anti-SARS-CoV-2 antibodies. Elecsys Anti-SARS-CoV-2 cobas® by Roche and LIAISON® SARS-CoV-2 S1/S2 IgG assay by DiaSorin were used for detecting anti-SARS-CoV-2 antibodies in all serum samples. Analyses were performed according to the manufacturer's instructions by using cobas® and LIAISON® XL Analyzer platforms. In brief, Elecsys by Roche uses a recombinant SARS-CoV-2 nucleocapsid (N) antigen. The electrochemiluminescence immunoassay (ECLIA) can detect the presence of IgG, IgM, and IgA antibodies recognizing the N protein. 10 According to the producer, samples positive for anti-SARS-CoV-2 antibodies show a cutoff index (COI) equal to or greater than 1. All samples with a COI < 1.0 are considered negative for the presence of SARS-CoV-2 antibodies. The SARS-CoV-2 S1/S2 IgG assay by DiaSorin can detect IgG antibodies directed against two recombinant SARS-CoV-2 proteins: the S1 and S2 which are involved in both docking and fusion processes of the virus. 11 According to manufacturer instructions, the test by Virus stocks were titrated using both Plaque Reduction Assay (PRA, PFU/ml) and Endpoint Dilutions Assay (EDA, TCID 50 /ml). In PRA, confluent monolayers of Vero E6 cells were infected with eight 10-fold dilutions of virus stock. After 1 h of adsorption at 37°C, the cell-free virus was removed. Cells were then incubated for 48 h in DMEM containing 2% FBS and 0.5% agarose. Cells were fixed and stained, and viral plaques were counted. In EDA, Vero E6 cells were seeded into 96 wells plates and infected at 95% of confluency with base 10 dilutions of virus stock. After 1 h of adsorption at 37°C, the cell-free virus was removed, cells were washed with PBS 1×, and complete medium was added to cells. After 48 h, cells were observed to evaluate the presence of a cytopathic effect (CPE). TCID 50 /ml of viral stocks were then determined by applying the Reed-Muench formula. Vero E6 cells were seeded into 96 wells plates 24 h before the experiment performed at 95% cell confluency for each well. Test performances were evaluated by sensitivity and specificity with the associated standard error (SE) and 95% confidence interval (CI). Differences between sensitivities and specificities, respectively, were assessed by exact binomial test for paired study design. 12 The overall performances were also measured, by means of the ROC curves and the associated area under the curve (AUC). For graphical purposes, we considered smooth ROC curves based on kernel estimators 13 with unbiased cross-validation bandwidth selection. We verified differences between AUCs by means of stratified bootstrap resampling for paired data. 14 Pre-pandemic sera were tested with DiaSorin and Roche diagnostic assays ( Figure 1A ). Three out of 85 samples tested positive with DiaSorin, and one tested as undetermined (12. Figure 1C ). As the previous analysis showed that no specific neutralizing activity was detected at T0, all remaining sera were tested at T15. The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. http://orcid.org/0000-0003-0185-3147 Alessandro Ambrosi http://orcid.org/0000-0003-1976-5663 Nicola Clementi http://orcid.org/0000-0002-1822-9861 Levels of SARS-CoV-2 specific antibodies detected with the tests by Roche and DiaSorin are also indicated (•, green and blue lines). Red dots indicate patients admitted to ICU. B, Spearman correlation analyses between values obtained with the two diagnostic methods and neutralizing activity of sera at 1:100 dilution Levels of SARS-CoV-2 specific antibodies detected with the tests by Roche and DiaSorin are also indicated (•, green and blue lines). Red dots indicate patients admitted to ICU. B, Spearman correlation analyses between values obtained with the two diagnostic methods and neutralizing activity of sera at 1:200 dilution REFERENCES 1 Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection 1-24 Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge Clinical performance of two SARS-CoV-2 serologic assays Elecsys® Anti-SARS-CoV-2 Immunoassay for the qualitative detection of antibodies against SARS-CoV-2 Statistical Methods in Diagnostic Medicine Smooth non-parametric receiver operating characteristic (ROC) curves for continuous diagnostic tests Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS-CoV-2 commercial chemiluminescent microparticle immunoassay for detection of IgG anti SARS-CoV-2 antibodies Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv Universal coronavirus vaccines: the time to start is now SARS-CoV-2 vaccines: status report SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Viral infection neutralization tests: A focus on severe acute respiratory syndromecoronavirus-2 with implications for convalescent plasma therapy Clinical and analytical performance of an automated serological test that identifies S1/S2 neutralizing IgG in covid-19 patients semiquantitatively Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects